TBPH

Theravance Biopharma TBPH reported first-quarter 2026 adjusted earnings of 1 cent per share, beating the Zacks Consensus Estimate of breakeven earnings. In the year-ago quarter, the company had incurred an adjusted loss of 17 cents per share. Total revenues in the quarter were $17.7 million, slightly short of the Zacks Consensus Estimate of $18 million. Revenues surged 15% year over year, driven by growth in collaboration revenues for Yupelri sales and improved operating leverage. Year to date, shares of Theravance have declined 9.1% against the industry’s 0.9% growth. Image Source: Zacks Investment Research Theravance’s top line consisted solely of collaboration revenues from partner Viatris VTRS tied to Yupelri (revefenacin) sales in the United States. Theravance and VTRS have collaborated on the development and commercialization of Yupelri, which is approved in the United States for the maintenance treatment of patients with chronic obstructive pulmonary disease. Viatris and Theravance share U.S. profits and losses associated with the commercialization of Yupelri. While Viatris gets 65% of the profits, Theravance receives 35%. Viatris' collaboration revenues include Theravance’s 35% share of Yupelri net sales, as well as its proportionate amount of the total shared costs incurred by the two companies. In March, Theravance and Viatris reached a settlement agreement with Mankind Pharma, granting the company a license to launch a generic version of Yupelri beginning April 23, 2039. Research and development expenses (excluding share-based compensation) totaled $5.2 million, down 49.8% from the year-ago quarter’s level, driven by cost savings from the restructuring announced in March and the ongoing wind-down of the CYPRESS study on its lead candidate, ampreloxetine. Selling, general and administrative expenses (excluding share-based compensation) increased 2.1% year over year to $14.9 million. As of March 31, 2026, Theravance had cash, cash equivalents and marketable securities worth $394.7 million compared with $326.5 million as of Dec. 31, 2025. In early March, Theravance announced disappointing top-line data from the pivotal phase III CYPRESS study, which evaluated its lead pipeline candidate, ampreloxetine, a norepinephrine reuptake inhibitor for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy, a pr...

YUPELRIﾮ Collaboration Revenue increased 15% year-over-year1, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage All Hatch-Waxman litigation relating to YUPELRIﾮ has been resolved following settlement with Mankind Pharma in March Organizational restructuring and cost reduction initiatives on track; delivered ~20% reduction in Operating Expenses year-over-year (excluding restructuring items) Q1 2026 TRELEGY net sales, reported by GSK, of $873 million, up 2% year-over-year; high confidence in achieving the $100 million 2026 milestone payment2 Strategic Review Committee actively evaluating a range of opportunities to maximize shareholder value Quarter-end cash balance of $395 million and no debt DUBLIN, May 7, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first quarter of 2026. "We delivered strong financial performance in the first quarter, reinforcing the quality of our commercial asset, our robust balance sheet and the important actions underway to reshape our cost structure, following the outcome of the CYPRESS study," said Rick E Winningham, Chief Executive Officer of Theravance Biopharma. "YUPELRIﾮ continues to deliver sustained net sales growth and expanding profitability, supported by growing community and hospital adoption, improved net pricing, and the recent resolution of generic litigation, driving increased long-term value for the franchise. TRELEGY also continued to perform well, and we remain confident that we will achieve the $100 million milestone payment associated with 2026 net sales. The entire Theravance team is acting with discipline and urgency, and we are confident that the continued execution against our strategic priorities and the Board's ongoing review process will maximize value for shareholders." Strategic Review Committee In 2024, the Theravance Board of Directors formed a Strategic Review Committee (the "Committee") composed entirely of independent directors to assess all strategic alternatives available to the Company. Since then, the Committee has been working on an ongoing basis with Lazard, its independent financial advisor, to evaluate opportunities to maximize shareholder value, including under multiple potential outcomes for the CYPRESS study, which the C...

SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Theravance Biopharma Inc. (TBPH) on Thursday reported a loss of $4.9 million in its first quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 10 cents. Earnings, adjusted for one-time gains and costs, came to 1 cent per share. The biopharmaceutical company posted revenue of $17.7 million in the period, which did not meet Street forecasts. Four analysts surveyed by Zacks expected $17.9 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TBPH at https://www.zacks.com/ap/TBPH

Corcept Therapeutics CORT incurred a first-quarter 2026 loss of 30 cents per share, in line with the Zacks Consensus Estimate. In the year-ago quarter, the company had reported earnings of 17 cents per share. First-quarter revenues rose 4.9% year over year to $164.9 million but missed the Zacks Consensus Estimate of $172 million. The top line consisted solely of product sales from Cushing’s syndrome drug Korlym. Revenues from Korlym, however, missed our model estimate of $169.3 million. Year to date, shares of Corcept have rallied 33.7% against the industry’s decline of 2.5%. Image Source: Zacks Investment Research Corcept’s first-quarter 2026 sales were driven by its established Cushing’s syndrome franchise, with management highlighting rising demand for Korlym. The company said March and April marked all-time highs in the number of patients starting treatment, following completion of a transition to a new pharmacy vendor earlier in the quarter. Importantly, management framed the period as a turning point for the business model. With the recent FDA approval of Lifyorli (relacorilant), the company expects future quarters to reflect sales from more than one medication, expanding its commercial footprint. In March 2026, the FDA approved Corcept’s selective glucocorticoid receptor antagonist, Lifyorli (relacorilant), in combination with nab-paclitaxel for the treatment of adult patients with platinum-resistant ovarian cancer. Management noted that in April 2026, Lifyorli, in combination with nab-paclitaxel, was added to NCCN Guidelines as a preferred regimen, with early uptake described as vigorous. Research and development expenses increased 9.1% year over year to $66.3 million in the first quarter of 2026, reflecting continued investment across oncology and other pipeline programs. Meanwhile, selling, general and administrative expenses surged 60.3% year over year to $145.4 million, reflecting higher spending to support the launch of Lifyorli. Corcept ended March 31, 2026, with cash and investments of $515.4 million, down from $532.4 million as of Dec 31, 2025. CORT raised its full-year 2026 revenue guidance to $950 million-$1.05 billion, signaling increased confidence as it transitions to a multi-product company. Previously, the company expected total revenues in the range of $900 million to $1 billion in 2026. The Zacks Consensus Estimate for revenues is pe...

Theravance Biopharma TBPH reported fourth-quarter 2025 adjusted earnings of 6 cents per share, which missed the Zacks Consensus Estimate of 44 cents. In the year-ago quarter, the company had incurred an adjusted loss of 5 cents per share. Total revenues in the quarter were $45.9 million, which missed the Zacks Consensus Estimate of $60 million. Revenues surged 145% year over year, driven primarily by $25 million of licensing and milestone revenues from partner Viatris VTRS tied to Yupelri (revefenacin) sales in the United States. Year to date, shares of Theravance have lost 25.1% compared with the industry’s 3.1% decline. Image Source: Zacks Investment Research The company’s top line consisted of collaboration revenues, along with licensing and milestone revenues tied to Viatris’ Yupelri sales in the reported quarter. Collaboration revenues amounted to $20.8 million, up 11.4% year over year. The company also recorded $25 million in licensing and milestone revenues associated with Yupelri sales. Theravance and VTRS have collaborated on the development and commercialization of Yupelri, which is approved in the United States for the maintenance treatment of patients with chronic obstructive pulmonary disease. Viatris and Theravance share U.S. profits and losses received in connection with the commercialization of Yupelri. While Viatris gets 65% of the profits, Theravance receives 35%. Viatris' collaboration revenues include Theravance’s 35% share of net sales of Yupelri, as well as its proportionate amount of the total shared costs incurred by the two companies. Research and development expenses (excluding share-based compensation) totaled $6.4 million, down 21% from the year-ago quarter’s level, driven by the near-completion of the CYPRESS study. Selling, general and administrative expenses (excluding share-based compensation) increased around 6.4% year over year to $15 million. As of Dec. 31, 2025, Theravance had cash, cash equivalents and marketable securities worth $326.5 million compared with $332.7 million as of Sept. 30, 2025. For 2025, Theravance reported total revenues of $107.4 million, which rose 67% year over year. For full-year 2025, the company recorded an adjusted loss of 14 cents per share, narrower than the prior-year reported loss of 33 cents. Earlier this month, Theravance announced top-line data from the pivotal phase III CYPRESS study, whic...

Theravance Biopharma (TBPH) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.44 per share. This compares to a loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -86.47%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.03 per share when it actually produced earnings of $0.04, delivering a surprise of +233.33%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Theravance Bio, which belongs to the Zacks Medical - Drugs industry, posted revenues of $45.89 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 23.28%. This compares to year-ago revenues of $18.75 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Theravance Bio shares have lost about 26.1% since the beginning of the year versus the S&P 500's decline of 3.2%. While Theravance Bio has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Theravance Bio was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Z...

Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate $60 - $70 million of annualized cash flow starting in Q3 2026 Strategic Review Committee accelerating evaluation of opportunities to maximize shareholder value YUPELRIﾮ achieved record brand profitability for Q4 and full-year 2025; full-year net sales of $266.6 million, recognized by Viatris, up 12% year-over-year1 resulting in a $25 million milestone payment Full-year 2025 TRELEGY net sales, reported by GSK, of $3.9 billion, up 12% year-over-year, triggered a $50 million milestone payment; high confidence in achieving the $100 million 2026 milestone payment2 All-time high non-GAAP profitability achieved for the second consecutive quarter3 Company expects to have approximately $400 million in cash at the end of Q1 2026 and no debt DUBLIN, March 19, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the fourth quarter and full year of 2025. "We ended 2025 on a positive note from a financial perspective, achieving another record quarter of non-GAAP profitability, hitting a new all-time high for YUPELRIﾮ brand-level profitability, and reaching $75 million in key sales-based milestones. These results highlight the strength and durability of our commercial asset, YUPELRIﾮ, our commitment to operating with financial and operational discipline, and the strength of our balance sheet," said Rick E Winningham, Chief Executive Officer of Theravance Biopharma. "Since announcing the CYPRESS study results earlier this month, we have made progress implementing an organizational restructuring to streamline costs and align resources with the commercial opportunity ahead of YUPELRIﾮ. We are confident that these actions, paired with the important work that the Board's Strategic Review Committee is doing to evaluate opportunities available to the Company, will enable Theravance to deliver on our goal of maximizing value for shareholders." Strategic Review Committee In 2024, the Theravance Board of Directors formed a Strategic Review Committee (the "Committee") composed entirely of independent directors to assess all strategic alternatives available to the Company. Since then, the Committee has been working on an ongoing bas...

SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Theravance Biopharma Inc. (TBPH) on Thursday reported fourth-quarter profit of $61 million. On a per-share basis, the South San Francisco, California-based company said it had profit of $1.15. Earnings, adjusted for non-recurring gains, were 6 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 44 cents per share. The biopharmaceutical company posted revenue of $45.9 million in the period, which also fell short of Street forecasts. Five analysts surveyed by Zacks expected $59.8 million. For the year, the company reported profit of $105.9 million, or $2.06 per share. Revenue was reported as $107.5 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TBPH at https://www.zacks.com/ap/TBPH

Irenic Capital Management initiated a new position in SPS Commerce (NASDAQ:SPSC), acquiring 452,066 shares in the fourth quarter, according to a February 17, 2026, SEC filing. Irenic Capital Management disclosed a new stake in SPS Commerce (NASDAQ:SPSC), purchasing 452,066 shares during the fourth quarter of 2025. The position's value at quarter-end was $40.3 million, according to the SEC filing dated February 17, 2026. This was a new position for Irenic Capital, representing 2.7% of its $1.49 billion in reportable U.S. equity holdings as of December 31, 2025. Top five holdings after the filing: NYSE: ITGR: $99.11 million (13.7% of AUM) NASDAQ: SHC: $67.00 million (9.3% of AUM) NASDAQ: TBPH: $51.66 million (7.1% of AUM) NASDAQ: ALKT: $48.60 million (6.7% of AUM) NYSE: WK: $47.61 million (6.6% of AUM) As of February 17, 2026, shares of SPS Commerce were priced at $60.06, down 60% over the past year and significantly underperforming the S&P 500’s roughly 13% gain in the same period. SPS Commerce offers cloud-based supply chain management solutions, including fulfillment automation and analytics tools, with complementary products for order management and vendor onboarding. The firm generates revenue through subscription-based software services that automate and optimize electronic communication and compliance across trading partners. It serves retailers, suppliers, grocers, distributors, and logistics firms seeking to enhance omnichannel order management and supply chain visibility. SPS Commerce, Inc. is a leading provider of cloud-based supply chain management solutions, enabling automation and enhanced analytics for a diverse customer base. The company leverages a scalable SaaS platform to drive operational efficiency and compliance in complex trading ecosystems. Its strategic focus on automation and data-driven insights positions it as a key technology partner for organizations navigating omnichannel retail and distribution challenges. Capital allocators do not usually wade into a stock down 60% unless they believe the underlying machine still works or at the very least can. As far as SPS Commerce, the firm just delivered its 100th consecutive quarter of revenue growth, with fourth quarter revenue up 13% to $192.7 million and recurring revenue up 14% year over year. Full-year revenue, meanwhile, climbed 18% to $751.5 million, while adjusted EBITDA rose 24% t...

A month has gone by since the last earnings report for Theravance Biopharma (TBPH). Shares have lost about 3.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Theravance Bio due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Theravance reported third-quarter 2025 adjusted earnings of 4 cents per share against the Zacks Consensus Estimate of a loss of 3 cents. In the year-ago quarter, the company had incurred an adjusted loss of 6 cents per share. Total revenues in the third quarter came in at $20 million, in line with the Zacks Consensus Estimate. Revenues surged 19% year over year, owing to increased collaboration revenues from partner Viatris. The top line solely comprised Viatris’ collaboration revenues in relation to Yupelri sales during the third quarter. Research and development expenses (excluding share-based compensation) totaled $7 million, down almost 14.6% from the year-ago quarter’s level. Selling, general and administrative expenses (excluding share-based compensation) increased around 13.8% year over year to $14.8 million. As of Sept. 30, 2025, Theravance had cash, cash equivalents and marketable securities worth $332.7 million compared with $338.8 million as of June 30, 2025. Theravance reaffirmed its financial guidance for 2025. The company continues to expect adjusted R&D expenses (excluding share-based compensation) in the $32-$38 million range in 2025. Adjusted SG&A expenses (excluding share-based compensation) are still projected between $50 million and $60 million. Theravance continues to expect share-based compensation expenses of $18-$20 million in 2025. Theravance expects adjusted margin in the fourth quarter of 2025 to be similar to third-quarter levels. In the past month, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted 230.16% due to these changes. Currently, Theravance Bio has a strong Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. Charting a somewhat similar path, the stock has a grade of C on the value side, putting it in the middle 20% for this investment strategy. Overall, the stock has an aggregat...

YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year 1 , and achieved record brand profitability Open-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026 Company to host an ampreloxetine focused virtual Key Opinion Leader (KOL) event for investors on December 8, 2025 TRELEGY year-to-date sales on track to achieve $50 million milestone in 2025 2 Strong balance sheet with $333 million in cash and no debt DUBLIN, Nov. 10, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2025. "Theravance delivered strong results in the third quarter, highlighted by record YUPELRI net sales and the achievement of non-GAAP breakeven, underscoring our commitment to financial and operational discipline," said Rick E Winningham, Chief Executive Officer of Theravance Biopharma. "In parallel, we continue to advance ampreloxetine toward topline results from the pivotal Phase 3 CYPRESS study in the first quarter of 2026. Backed by a strong balance sheet, durable YUPELRI cash flow, and multiple high-value milestones ahead, we approach this important catalyst from a position of strength—ready to deliver results that could transform the standard of care for multiple system atrophy patients and drive lasting value for patients and shareholders." Operational Highlights: YUPELRI ® (revefenacin) inhalation solution, the first and only once-daily, nebulized LAMA (long-acting muscarinic antagonist) bronchodilator approved in the U.S. for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD): Achieved all-time high U.S. net sales of $71.4 million in Q3 2025, increasing 15% year-over-year (YoY) (Q3 2025 vs Q3 2024)1 driven by customer demand growth of 6% YoY (Q3 2025 vs Q3 2024)3 and improved net pricing due to favorable channel mix. Approximately $54 million required in Q4 2025 to trigger $25 million milestone for the achievement of $250 million of net sales in 2025.4 Increased doses pulled through the hospital channel by 29% YoY (Q3 2025 vs Q3 2024), reflecting another quarter of strong momentum.5 Presented two oral presentations at the 2025 CHEST Annual Meeting that further support YUPELRI as an effective maintenan...

This article first appeared on GuruFocus. Release Date: November 10, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Theravance Biopharma Inc (NASDAQ:TBPH) achieved non-GAAP break-even in Q3 2025, highlighting strong financial discipline and business model strength. The company reported record net sales and profitability for its product Uelri, driven by increased demand and favorable pricing. Theravance Biopharma Inc (NASDAQ:TBPH) is on track to achieve near-term milestones totaling $75 million in Q4 2025, enhancing its financial position. The pivotal phase 3 Cyprus trial for ampraloxetine is progressing well, with data readout expected in early 2026, potentially transforming the company's value. The company ended the quarter with $333 million in cash and no debt, providing a strong financial foundation for future growth and investment. The success of Theravance Biopharma Inc (NASDAQ:TBPH) heavily relies on the upcoming Cyprus trial results, which introduces uncertainty and risk. The company faces executional challenges in conducting clinical trials for rare diseases, which could impact timelines and outcomes. Despite strong performance, the company needs to manage potential expenses related to the launch of ampraloxetine, which could affect profitability. There is a dependency on milestone payments from partners, which, if delayed or unmet, could impact financial projections. The company's focus on a limited number of pipeline assets may limit diversification and increase vulnerability to setbacks in key projects. Warning! GuruFocus has detected 7 Warning Signs with TBPH. Is TBPH fairly valued? Test your thesis with our free DCF calculator. Q: Given the continued outperformance and potential additional cash inflow, how much capital does Theravance need to retain for the potential launch of Amproloxetine? A: Rick Winningham, CEO: The financial strength of the company is a key element of value. The strategic review committee is considering the timing and amount of capital return. The launch of Amproloxetine will be efficient, not heavily burdening the P&L. The focus is on executing the Cyprus study and obtaining top-line results before making decisions on capital return. The company is in a strong financial position, allowing for potential capital return if desired by the board. Q: Are there any plans...